# An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer

> **NCT00561197** · PHASE1,PHASE2 · TERMINATED · sponsor: **Ascenta Therapeutics** · enrollment: 13 (actual)

## Conditions studied

- Locally Advanced Esophageal or GE Junction Cancer

## Interventions

- **DRUG:** AT-101

## Key facts

- **NCT ID:** NCT00561197
- **Lead sponsor:** Ascenta Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-08
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Drug not being developed for this indication
- **Last updated:** 2013-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00561197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00561197, "An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00561197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*